

Claim Listing

This listing of claims will replace all prior versions, and listings, of claims in the application.

1-14. Cancelled.

15. (Currently amended) ~~A therapeutic agent comprising:~~

[[a]] A fused or chimeric polypeptide comprising

a first component ~~comprising~~ including a polypeptide that specifically binds to at least one of $\alpha 6\beta 1$ integrin receptor and $\alpha 6\beta 4$ integrin receptor, wherein the polypeptide comprises the G3 subdomain of the laminin-5 $\alpha 3$ chain or a fragment, ~~mutant, homolog, or ortholog, analog, or allele~~ thereof, and

a second component chemically bound to said first component, wherein said second component ~~comprises~~ includes an agent for use in the destruction or neutralization of a pathogen comprising at least one of $\alpha 6\beta 1$ integrin receptor[[s]] and $\alpha 6\beta 4$ integrin receptor[[s]] on the surface of the pathogen.

16. (Currently amended) ~~The therapeutic agent~~ fused or chimeric polypeptide of claim 15, wherein the second component is a polypeptide.

17. (Withdrawn-currently amended) ~~The therapeutic agent~~ fused or chimeric polypeptide of claim 15, wherein the second component is a non-protein agent.

18. (Currently amended) ~~The therapeutic agent~~ fused or chimeric polypeptide of claim 15, wherein the second component is selected from the group consisting of IL-2, IL-3 IL-15, IL-12, IFN- γ , GM-CSF, CD40, CD40 ligand (CD40L), C3 Complement components, CD80, CD86, FAS, FAS ligand (FASL), superantigens, muramyl dipeptide (MDP), lipopolysaccharide (LPS), ~~[[or]]~~ and mannose.

19. (Currently amended) ~~The therapeutic composition~~ fused or chimeric polypeptide of claim 15, wherein the first component comprises at least about 70% sequence identity with SEQ ID NO:2.

20. (Currently amended) ~~The therapeutic composition~~ fused or chimeric polypeptide of claim 15, wherein the first component comprises at least about 70% sequence identity with SEQ ID NO:4.

21. (Currently amended) The ~~therapeutic composition~~ fused or chimeric polypeptide of claim 15, wherein the first component comprises at least about 70% sequence identity with SEQ ID NO:6.

22-42. Cancelled.

43. (Currently amended) The ~~therapeutic composition~~ fused or chimeric polypeptide of claim 15, wherein the first component comprises at least about 90% sequence identity with SEQ ID NO:2.

44. (Currently amended) The ~~therapeutic composition~~ fused or chimeric polypeptide of claim 15, wherein the first component comprises at least about 90% sequence identity with SEQ ID NO:4.

45. (Currently amended) The ~~therapeutic composition~~ fused or chimeric polypeptide of claim 15, wherein the first component comprises at least about 90% sequence identity with SEQ ID NO:6.

46. (Currently amended) The ~~therapeutic composition~~ fused or chimeric polypeptide of claim 15, wherein the first component consists of SEQ ID NO:6.

47. (Currently amended) The ~~therapeutic composition~~ fused or chimeric polypeptide of claim 15, wherein the first component comprises a segment consisting of SEQ ID NO:6.

48. (Currently amended) A fused or chimeric polypeptide comprising a first component comprising a first polypeptide, wherein the first polypeptide comprises at least a segment of the G-domain of a laminin-5 $\alpha 3$ chain and the first polypeptide specifically binds to at least one of $\alpha 6\beta 1$ integrin receptor and $\alpha 6\beta 4$ integrin receptor, ~~that~~ wherein the at least one of $\alpha 6\beta 1$ integrin receptor and $\alpha 6\beta 4$ integrin receptor specifically binds to a second polypeptide comprising a segment consisting of SEQ ID NO:2, and

a second component chemically bound to said first component wherein said second component includes an agent for use in the destruction or neutralization of a pathogen comprising at least one of $\alpha 6\beta 1$ integrin receptor and $\alpha 6\beta 4$ integrin receptor on the surface of the pathogen.

49. (Previously presented) The fused or chimeric polypeptide of claim 48, wherein the second component is a polypeptide.

50. (Withdrawn) The fused or chimeric polypeptide of claim 48 wherein the second component is a non-protein agent.

51. (Currently amended) A fused or chimeric polypeptide comprising a first component comprising a first polypeptide, wherein the first polypeptide comprises at least a segment of the G-domain of a laminin-5 $\alpha 3$ chain and the first polypeptide specifically binds to at least one of $\alpha 6\beta 1$ integrin receptor and $\alpha 6\beta 4$ integrin receptor, ~~that~~ wherein the at least one of $\alpha 6\beta 1$ integrin receptor and $\alpha 6\beta 4$ integrin receptor specifically binds to a second polypeptide comprising a segment consisting of SEQ ID NO:4, and
a second component chemically bound to said first component wherein said second component includes an agent for use in the destruction or neutralization of a pathogen comprising at least one of $\alpha 6\beta 1$ integrin receptor and $\alpha 6\beta 4$ integrin receptor on the surface of the pathogen.

52. (Previously presented) The fused or chimeric polypeptide of claim 51, wherein the second component is a polypeptide.

53. (Withdrawn) The fused or chimeric polypeptide of claim 51 wherein the second component is a non-protein agent.

54. (Currently amended) A fused or chimeric polypeptide comprising a first component comprising a first polypeptide, wherein the first polypeptide comprises at least a segment of the G-domain of a laminin-5 $\alpha 3$ chain and the first polypeptide specifically binds to at least one of $\alpha 6\beta 1$ integrin receptor and $\alpha 6\beta 4$ integrin receptor, ~~that~~ wherein the at least one of $\alpha 6\beta 1$ integrin receptor and $\alpha 6\beta 4$ integrin receptor specifically binds to a second polypeptide comprising a segment consisting of SEQ ID NO:6, and
a second component chemically bound to said first component wherein said second component includes an agent for use in the destruction or neutralization of a pathogen comprising at least one of $\alpha 6\beta 1$ integrin receptor and $\alpha 6\beta 4$ integrin receptor on the surface of the pathogen.

55. (Previously presented) The fused or chimeric polypeptide of claim 54, wherein the second component is a polypeptide.

56. (Withdrawn) The fused or chimeric polypeptide of claim 54 wherein the second component is a non-protein agent.